Better Buy: WELL Health Stock or Docebo?

I am more bullish on WELL Health than Docebo due to its cheaper valuation and high growth prospects.

| More on:
telehealth stocks

Image source: Getty Images

Growth stocks generally grow their financials at a higher rate than the industry average, thus delivering superior returns. However, these companies require higher capital to fund their growth. So, the rising interest rates and recession fears have made investors skeptical, thus leading to a selloff last year.

Yet, with the beginning of the new year, investors’ optimism appears to have returned. Growth stocks are witnessing healthy buying. With the focus returning to growth stocks, which among WELL Health Technologies (TSX:WELL) and Docebo (TSX:DCBO) would be a good buy right now? Let’s compare their recent performances, growth prospects, and valuations.

WELL Health Technologies

WELL Health is a digital healthcare company that allows healthcare practitioners to provide virtual healthcare services through its platform. Despite broader economic headwinds, the company delivered solid financials last year. Supported by strategic acquisitions and robust growth in its virtual services, its revenue grew by 121% in the first nine months of 2022. Virtual services accounted for 33% of its revenue compared to 24% in the corresponding period of the previous year.

With the growth in higher-margin virtual services, WELL Health’s margins also expanded, driving its bottom line, which grew by 559%. It also generated an adjusted EBITDA (earnings before interest, depreciation, tax, and amortization) of $77.4 million during the three quarters.

Meanwhile, I expect the upward momentum to continue amid the growing popularity of telehealthcare services and the expansion of the company’s footprint in the United States and Canada. Markets and Markets projects global telehealthcare services to grow at an annualized rate of 26.6% through 2030. So, the company’s outlook looks healthy.

Meanwhile, WELL Health has outperformed the broader equity markets this year, with returns of 16.6%. Despite the recent increase, it still trades at a discount of over 40% compared to its 52-week high, while its NTM (next 12 months) price-to-sales multiple stands at an attractive 1.2.

Docebo

Docebo is a Canadian software company offering learning management solutions (LMS) worldwide. Supported by its expanding customer base and average contract value, the company has grown its top line at an annualized rate of 59.7% since 2016. The uptrend continued in 2022 as well, with its revenue growing by 40% to $104 million in the first nine months. Its adjusted EBITDA losses have declined from $6.5 million to $0.97 million, with the company reporting a positive adjusted EBITDA of $0.6 million in the third quarter.

The LMS market is expanding amid the increased adoption of digital tools across various sectors. Meanwhile, Fortune Business Insights projects the global LMS market to grow at an annualized rate of 14.2% through 2029 to reach US$40.95 billion. Given its highly configurable artificial intelligence-powered platform, the company is well-positioned to benefit from market expansion. Also, its innovative product launches and multi-year contracts with clients could boost its growth in the coming years.

However, amid the weakness in growth stocks, Docebo has lost over 34% of its stock value compared to its 52-week high while trading at 6.9 times its projected sales for the next four quarters.

Bottom line

Although both companies look attractive at these levels, I am bullish on WELL Health due to its higher growth prospects and cheaper valuation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. The Motley Fool recommends Docebo. The Motley Fool has a disclosure policy.

More on Tech Stocks

A child pretends to blast off into space.
Tech Stocks

Here’s Exactly How a $20,000 TFSA Could Grow Into $100,000 by 2030

Here's why Canadian investors should consider owning growth stocks such as Electrovaya and Propel in their TFSA portfolio right now.

Read more »

Bitcoin
Tech Stocks

Want to Bet on the Blockchain Boom? Buy These 2 Stocks Right Now

Investing in crypto stocks such as Coinbase is a good strategy for those looking to gain exposure to Bitcoin in…

Read more »

diversification is an important part of building a stable portfolio
Dividend Stocks

TFSA: 3 Strong Canadian Stocks to Buy and Hold for Life

Looking for the perfect portfolio? Get on these three right away!

Read more »

diversification and asset allocation are crucial investing concepts
Tech Stocks

Why I’m More Excited About This Stock Than Any Other Investment

Among all the stocks I hold, this one has completely changed how I think about long-term investing.

Read more »

doctor uses telehealth
Tech Stocks

2 Value Stocks Everyone Is Selling But I’m Buying

Considering their growth prospects and discounted stock prices, these stocks offer excellent buying opportunities for long-term investors.

Read more »

Person uses a tablet in a blurred warehouse as background
Tech Stocks

1 Magnificent AI Stock Down 21% That Could Transform Your Portfolio

If you’re looking for a practical AI stock with strong fundamentals and untapped potential, Descartes might be the one to…

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

How I’d Build the Ultimate Tech Portfolio With $15,000

These tech stocks are well-positioned to generate strong returns due to their leadership in AI, digital transformation, and semiconductors.

Read more »

Young adult concentrates on laptop screen
Tech Stocks

Up 60% Since April, Is Shopify Stock a Good Buy Now?

Given its solid underlying business, healthy financial growth, and high growth prospects, the uptrend in Shopify will continue.

Read more »